1915 completed, 264 terminated, 146 active not recruiting, 114 recruiting. 698 Phase 2, 681 Phase 3, 549 Phase 1, 254 Phase 4, 86 Not applicable.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 698 | Completed 452, Terminated 100, Active not recruiting 57, Recruiting 45, Unknown 21, Withdrawn 16, Not yet recruiting 7 |
| Phase 3 | 681 | Completed 471, Terminated 74, Active not recruiting 64, Recruiting 41, Unknown 16, Withdrawn 9, Not yet recruiting 5, Enrolling by invitation 1 |
| Phase 1 | 549 | Completed 424, Terminated 54, Active not recruiting 30, Recruiting 24, Withdrawn 9, Not yet recruiting 5, Unknown 3 |
| Phase 4 | 254 | Completed 204, Terminated 28, Unknown 8, Withdrawn 7, Active not recruiting 5, Recruiting 2 |
| Not applicable | 86 | Completed 69, Unknown 5, Terminated 4, Recruiting 3, Withdrawn 3, Enrolling by invitation 1, Not yet recruiting 1 |
| Early Phase 1 | 3 | Completed 2, Terminated 1 |
Follow Hoffmann-La Roche: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
Glofitamab, Radiotherapy, Obinutuzumab - Relapsed /Refractory DLBCL | Phase 2 | Not yet recruiting | Olivia Newton-John Cancer Research Institute | 40 | 2026-12-01 | 2026-06-08 |
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Belamaf, Cevostamab, Pomalidomide - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | 108 | 2026-12-01 | 2026-09-21 |
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Faricimab, Sham - Central Serous Chorioretinopathy (CSC) | Phase 2 | Not yet recruiting | Singapore National Eye Centre | 50 | 2026-12-01 | 2026-07-02 |
A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications
Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 948 | 2026-12-01 | 2026-10-22 |
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
Trontinemab, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 1600 | 2026-11-30 | 2026-10-13 |
Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children
NXT007 - Hemophilia A | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 50 | 2026-11-30 | 2026-10-19 |
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
RO7845860 - Relapsing Multiple Sclerosis | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 85 | 2026-11-23 | 2026-10-09 |
A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Afimkibart, Placebo - Moderately to Severely Active Ulcerative Colitis | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 350 | 2026-11-15 | 2026-09-29 |
A Study to Assess the Effect of Subcutaneous Injection Site on the Pharmacokinetics of Pegozafermin in Healthy Participants
Pegozafermin - Healthy Volunteers | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 105 | 2026-11-05 | 2026-10-19 |
Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease
RO7568282, Placebo - Alzheimer's Disease | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 450 | 2026-10-31 | 2026-10-07 |
A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment
Giredestrant - Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 1500 | 2026-10-30 | 2026-10-15 |
Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myeloma
Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 2 | Recruiting | Hoffmann-La Roche | 45 | 2026-10-30 | 2026-10-15 |
A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)
Ocrelizumab co-formulated with rHuPH20 - Relapsing-remitting Multiple Sclerosis | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 25 | 2026-10-30 | 2026-10-14 |
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Inavolisib, Fulvestrant, Palbociclib - Breast Cancer, Diabetes Type II | Phase 2 | Recruiting | Hoffmann-La Roche | 40 | 2026-10-30 | 2026-10-20 |
A Study of RO7821657 in Participants With Solid Tumors
RO7821657 - Locally Advanced or Metastatic Solid Tumors | Phase 1 | Not yet recruiting | Hoffmann-La Roche | 405 | 2026-10-26 | 2026-10-20 |
A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RO7830698, Placebo - Chronic Obstructive Pulmonary Disease (COPD), Healthy Participants | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | 104 | 2026-10-20 | 2026-10-20 |
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
Baloxavir marboxil, Placebo - Influenza, Human, Respiratory Tract Infections | Phase 3 | Recruiting | Hoffmann-La Roche | 325 | 2026-10-16 | 2026-10-22 |
A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)
SPLIT Abs, 203Pb-DOTAM, 212Pb-DOTAM - Metastatic Colorectal Cancer | Phase 1 | Recruiting | Hoffmann-La Roche | 180 | 2026-10-06 | 2026-10-06 |
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Divarasib, Pembrolizumab, Nivolumab - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Hoffmann-La Roche | 400 | 2026-10-06 | 2026-10-13 |
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Petrelintide, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 3 | Recruiting | Hoffmann-La Roche | 600 | 2026-09-30 | 2026-10-07 |
Showing 20 of 2577. Sign in to see all of them.
Conditions studied
Breast Neoplasms (226) · Arthritis, Rheumatoid (191) · HIV Infections (108) · Hepatitis C, Chronic (107) · Colorectal Neoplasms (106) · Carcinoma, Non-Small-Cell Lung (104) · Anemia (98) · Neoplasms (78) · Diabetes Mellitus, Type 2 (73) · Hepatitis B, Chronic (51) · Melanoma (51) · Acquired Immunodeficiency Syndrome (46) · Lymphoma, Non-Hodgkin (39) · Leukemia, Lymphocytic, Chronic, B-Cell (38) · Lymphoma, Large B-Cell, Diffuse (37)
Interventions
Bevacizumab (208) · atezolizumab (207) · tocilizumab (175) · Rituximab (155) · Capecitabine (140) · peginterferon alfa-2a (132) · Trastuzumab (115) · Ribavirin (94) · Docetaxel (82) · Erlotinib Hydrochloride (76) · Paclitaxel (76) · obinutuzumab (75) · Carboplatin (72) · Cyclophosphamide (71) · continuous erythropoietin receptor activator (70)
Countries
United States (1067) · Spain (735) · France (713) · Germany (660) · Italy (631) · United Kingdom (622) · Canada (538) · Australia (446) · Poland (446) · Belgium (357) · Brazil (349) · South Korea (340) · Netherlands (314) · Mexico (294) · Russia (293)
Top investigators
Matthew Krebs, Dr (6) · Bettina Petersen (4) · Iris Vesper (4) · Norman Wolmark, MD (4) · Alexander de Vries, MD (3) · Guenther Steger, MD (3) · Randall J Bateman, MD (3) · Adriano Lazzarin, MD (2) · Andreas Buhr (2) · Anil Kukreja, MD (2)
Results publications
PMID 36791280, PMID 26965694, PMID 29244149, PMID 30649524, PMID 32445184, PMID 38620092, PMID 34037241, PMID 22491018, PMID 24983357, PMID 33241650, PMID 37148485, PMID 38700045, PMID 39807668, PMID 40258203, PMID 24429164, PMID 31050355, PMID 32746839, PMID 35511917, PMID 35939785, PMID 36310331, PMID 39758130, PMID 40603145, PMID 22256804, PMID 23457002, PMID 24265828, PMID 24329937, PMID 27816567, PMID 27939400, PMID 28057664, PMID 28117049, PMID 28433500, PMID 31838007, PMID 32450725, PMID 33217063, PMID 33476492, PMID 33693991, PMID 35672926, PMID 36163349, PMID 36792367, PMID 36795388, PMID 37146227, PMID 37185961, PMID 37391667, PMID 37585454, PMID 37652990, PMID 37678236, PMID 37951571, PMID 38190001, PMID 38197558, PMID 38758639
NIH funding
2023 (82), 2014 (64), 2008 (60), 2016 (55), 2015 (52), 2009 (50), 2017 (44), 2019 (39), 2018 (34), 2025 (28), 2005 (14), 2004 (11), R01AG046179 (3), U01AG042791 (3), R01AG053267 (2)